XRTX - XORTX Therapeutics Inc.

2.97
-0.060   -2.020%

Share volume: 81,988
Last Updated: 04-27-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.11%

PREVIOUS CLOSE
CHG
CHG%
$3.03
-0.06
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
7.22%
1 Month
675.46%
3 Months
476.59%
6 Months
370.09%
1 Year
180.19%
2 Year
12.29%
Key data
Stock price
$2.97
P/E Ratio 
0.00
DAY RANGE
$2.82 - $3.07
EPS 
N/A
52 WEEK RANGE
$0.34 - $3.60
52 WEEK CHANGE
$189.76
MARKET CAP 
6.097 M
YIELD 
N/A
SHARES OUTSTANDING 
2.904 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-16-2025
BETA 
-0.13
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$12,436,159
AVERAGE 30 VOLUME 
$3,782,221
Company detail
CEO: Allen W. Davidoff
Region: US
Website: xortx.com
Employees: 0
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

XORTX Therapeutics Inc. develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.

Recent news